Wave Life Sciences (WVE) Bank of America SMID Cap Virtual Conference summary

Event overview

• Virtual conference focused on US small and mid-cap companies, featuring presentations from nearly 20 firms over two days.

• Emphasis on biotech innovation, particularly RNA-based therapeutics, with deep dives into clinical pipelines and strategic direction.

Technology and platform insights

• Highlighted differentiated chemistry enabling RNA interference, editing, and splicing, supporting versatile therapeutic approaches.

• RNA editing offers redosable, non-permanent solutions with high specificity and safety, avoiding DNA mutation risks.

• Proprietary chemistry allows selection of optimal modality for each disease, demonstrated in programs like PNPLA3.

Pipeline and clinical progress

• WVE-007 (obesity) and alpha-1 antitrypsin deficiency (AATD) programs identified as transformative, with key data and regulatory milestones expected in the next 12 months.

• WVE-007 shows promising reductions in visceral and total body fat, with focus on maintenance therapy and combination potential.

• AATD program progressing toward potential accelerated approval, leveraging biomarker-driven endpoints and repeat dosing benefits.

• PNPLA3 asset entering clinic, targeting a large genetically defined population, with early biomarker readouts planned.